| Baseline | 3 months | p-value |
Major acute effect group¶ | | | |
WHO class II/III/IV n | 2/30/3 | 3/31/1 | |
6MWD m | 310±18 | 358±26 | 0.005 |
P̄pa mmHg | 47±2 | 42±3 | 0.05 |
CI L·min−1·m−2 | 2.0±0.1 | 2.5±0.2 | 0.001 |
PVR dyn·s·cm−5 | 916±66 | 632±112 | 0.002 |
Minor acute effect group+ | | |
WHO class II/III/IV n | 1/25/6 | 2/30/0 | |
6MWD m | 301±21 | 379±26 | 0.02 |
P̄pa mmHg | 46±2 | 43±2 | 0.4 |
CI L·min−1·m−2 | 2.3±0.1 | 2.7±0.2 | 0.005 |
PVR dyn·s·cm−5 | 770±61 | 624±82 | 0.03 |